Professor Sillence and his research team from Queensland University of Technology are testing drug velagliflozin as a possible treatment for horses and ponies with equine metabolic syndrome to help prevent endocrinopathic laminitis. Velagliflozin works by causing the kidneys to excrete more glucose in the urine to take the pressure off the pancreas and lower insulin levels. Velagliflozin has been trialed in Australia and is now being trialed in Europe.
Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M
The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies
PLoS ONE 13(9): e0203655 published 13 Sept 2018. https://doi.org/10.1371/journal.pone.0203655
See also: Drug shows promises in preventing laminitis in at-risk ponies - www.horsetalk.co.nz 24 Sept 2018
Giddy up: help for plump ponies is fast on its way - Dec 2018 Queensland University of Technology
Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M
The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies
PLoS ONE 13(9): e0203655 published 13 Sept 2018. https://doi.org/10.1371/journal.pone.0203655
See also: Drug shows promises in preventing laminitis in at-risk ponies - www.horsetalk.co.nz 24 Sept 2018
Giddy up: help for plump ponies is fast on its way - Dec 2018 Queensland University of Technology
RSS Feed